ChemoCentryx, Inc.

2019 Q3 Form 10-Q Financial Statement

#000119312519212993 Filed on August 05, 2019

View on sec.gov

Income Statement

Concept 2019 Q3 2019 Q2 2018 Q2

Balance Sheet

Concept 2019 Q3 2019 Q2 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $170.9M $199.4M $182.0M
YoY Change -1.28% 9.51% 49.65%
Cash & Equivalents $37.00M $38.75M $68.75M
Short-Term Investments $135.0M $160.6M $113.3M
Other Short-Term Assets $1.600M $2.600M $2.700M
YoY Change -38.46% -3.7% 17.39%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00 $164.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $172.5M $202.0M $184.9M
YoY Change -2.02% 9.24% 48.93%
LONG-TERM ASSETS
Property, Plant & Equipment $1.588M $1.496M $1.614M
YoY Change -0.38% -7.31% 59.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $34.90M $23.80M $19.80M
YoY Change 170.54% 20.2% 32.0%
Other Assets $1.354M $273.0K $306.0K
YoY Change 509.91% -10.78% -12.82%
Total Long-Term Assets $39.80M $27.81M $21.69M
YoY Change 170.87% 28.24% 32.55%
TOTAL ASSETS
Total Short-Term Assets $172.5M $202.0M $184.9M
Total Long-Term Assets $39.80M $27.81M $21.69M
Total Assets $212.3M $229.8M $206.6M
YoY Change 11.3% 11.23% 47.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $937.0K $974.0K $1.022M
YoY Change 62.67% -4.7% -25.67%
Accrued Expenses $17.60M $14.57M $11.02M
YoY Change 50.06% 32.27% 30.48%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $55.35M $56.66M $68.71M
YoY Change -9.74% -17.53% 53.74%
LONG-TERM LIABILITIES
Long-Term Debt $19.76M $19.74M $14.70M
YoY Change 34.19% 34.27%
Other Long-Term Liabilities $1.455M $1.777M $419.0K
YoY Change 242.35% 324.11% 138.07%
Total Long-Term Liabilities $21.22M $21.52M $15.12M
YoY Change 40.03% 42.3% 8490.34%
TOTAL LIABILITIES
Total Short-Term Liabilities $55.35M $56.66M $68.71M
Total Long-Term Liabilities $21.22M $21.52M $15.12M
Total Liabilities $150.5M $158.4M $177.7M
YoY Change -11.12% -10.89% 78.4%
SHAREHOLDERS EQUITY
Retained Earnings -$414.5M -$401.6M -$352.8M
YoY Change 13.95% 13.82% 9.47%
Common Stock $475.9M $472.7M $382.0M
YoY Change 23.49% 23.76% 5.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $61.86M $71.46M $28.90M
YoY Change
Total Liabilities & Shareholders Equity $212.3M $229.8M $206.6M
YoY Change 11.3% 11.23% 47.03%

Cashflow Statement

Concept 2019 Q3 2019 Q2 2018 Q2

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1496000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1536000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0
CY2019Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
273000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
390000
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38745000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28088000
CY2019Q2 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
0
CY2018Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
2058000
CY2019Q2 us-gaap Assets
Assets
229811000
CY2018Q4 us-gaap Assets
Assets
183310000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-374497000
CY2019Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2646000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2342000
CY2019Q2 us-gaap Assets Current
AssetsCurrent
202003000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
181384000
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
974000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
966000
CY2019Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
19738000
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
19689000
CY2019Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
80174000
CY2018Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
84100000
CY2019Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1777000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
387000
CY2019Q2 us-gaap Liabilities
Liabilities
158351000
CY2018Q4 us-gaap Liabilities
Liabilities
168572000
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
229811000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
183310000
CY2019Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14573000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12969000
CY2019Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
41115000
CY2018Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
50461000
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
56662000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
64396000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-198000
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-401596000
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
58000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
51000
CY2019Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
472661000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
389398000
CY2019Q2 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
16000
CY2018Q4 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
16000
CY2019Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
353000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
71460000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17624000
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17759000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5570000
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4748000
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
23194000
CY2018Q2 us-gaap Costs And Expenses
CostsAndExpenses
22507000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32978000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32501000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11071000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9408000
us-gaap Costs And Expenses
CostsAndExpenses
44049000
us-gaap Costs And Expenses
CostsAndExpenses
41909000
CY2019Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
7173000
CY2018Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
15022000
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7173000
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15022000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-16021000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7485000
CY2019Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1418000
CY2018Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
792000
CY2019Q2 us-gaap Interest Expense
InterestExpense
547000
CY2018Q2 us-gaap Interest Expense
InterestExpense
181000
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
871000
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
611000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
15500000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
24568000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15500000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24568000
us-gaap Operating Income Loss
OperatingIncomeLoss
-28549000
us-gaap Operating Income Loss
OperatingIncomeLoss
-17341000
us-gaap Investment Income Interest
InvestmentIncomeInterest
2539000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1405000
us-gaap Interest Expense
InterestExpense
1089000
us-gaap Interest Expense
InterestExpense
355000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1450000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1050000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-15150000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-6874000
CY2019Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
357000
CY2018Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
65000
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14793000
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6809000
us-gaap Net Income Loss
NetIncomeLoss
-27099000
us-gaap Net Income Loss
NetIncomeLoss
-16291000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
551000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-118000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26548000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16409000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
79267000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
25532000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
14738000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
80639000
us-gaap Cumulative Effect On Retained Earnings Net Of Tax1
CumulativeEffectOnRetainedEarningsNetOfTax1
-47331000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
8677000
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
473000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4629000
ccxi Adjustments To Additional Paid In Capital Compensation Expense Related To Options Granted To Consultants
AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToOptionsGrantedToConsultants
538000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
28898000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2423000
CY2018Q2 ccxi Adjustments To Additional Paid In Capital Compensation Expense Related To Options Granted To Consultants
AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToOptionsGrantedToConsultants
203000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
5568000
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1174000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5503000
ccxi Adjustments To Additional Paid In Capital Compensation Expense Related To Options Granted To Consultants
AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToOptionsGrantedToConsultants
97000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2841000
us-gaap Share Based Compensation
ShareBasedCompensation
5600000
CY2019Q2 ccxi Adjustments To Additional Paid In Capital Compensation Expense Related To Options Granted To Consultants
AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToOptionsGrantedToConsultants
57000
us-gaap Profit Loss
ProfitLoss
-27099000
us-gaap Profit Loss
ProfitLoss
-16291000
us-gaap Share Based Compensation
ShareBasedCompensation
5167000
us-gaap Depreciation
Depreciation
276000
us-gaap Depreciation
Depreciation
227000
ccxi Non Cash Interest Income Expense Net
NonCashInterestIncomeExpenseNet
1061000
ccxi Non Cash Interest Income Expense Net
NonCashInterestIncomeExpenseNet
480000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-2058000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-50926000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
340000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
475000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-117000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-53000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
8000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-378000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
29000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
2480000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-13272000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
8063000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33161000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
49292000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
236000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
631000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
154889000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
99762000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
116270000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
62450000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-33888000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-37943000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
73276000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5604000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
7881000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1174000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
473000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
77706000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
17383000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10657000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
28732000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28088000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40020000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38745000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68752000
us-gaap Interest Paid Net
InterestPaidNet
871000
us-gaap Interest Paid Net
InterestPaidNet
173000
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2273000
CY2018Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.26
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
58056
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49542
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.49
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.33
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55226
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49198
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
73276000
ccxi Operating Lease Rightofuse Asset Amortization
OperatingLeaseRightofuseAssetAmortization
523000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
4967000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2796000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11594537
CY2019Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
35660000
CY2019Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
160612000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11495993
CY2019Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13924000
CY2019Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
733000
CY2019Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
219685000
CY2019Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
358000
CY2019Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
5000
CY2019Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
23766000
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
175124000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
198000
CY2018Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
26030000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
148896000
CY2019Q2 us-gaap Cash
Cash
3100000
CY2018Q4 us-gaap Cash
Cash
2100000
CY2019Q2 ccxi Accrued Liabilities Research And Development Current
AccruedLiabilitiesResearchAndDevelopmentCurrent
9470000
CY2018Q4 ccxi Accrued Liabilities Research And Development Current
AccruedLiabilitiesResearchAndDevelopmentCurrent
8466000
CY2019Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2086000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2767000
CY2019Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1027000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
811000
CY2019Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1308000
CY2019Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
682000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
925000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
20000000
CY2019Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2686000
CY2018Q4 ccxi Operating Lease Obligation
OperatingLeaseObligation
387000
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
324000
CY2018Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
268000
us-gaap Operating Lease Cost
OperatingLeaseCost
592000
us-gaap Operating Lease Cost
OperatingLeaseCost
536000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
751000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1659000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2989000
CY2019Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
303000
CY2019Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y9M18D
CY2019Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.110
CY2019Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
7169000
CY2019Q2 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
-2860000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
15329000
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
-3517000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1708516
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10720200
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.39
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
2000000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
2046863
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1817042
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.62
ccxi Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsExercised
107619
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
871960
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.00
ccxi Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Expired Or Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsExpiredOrForfeited
679380
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
672713
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
7.25
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2448652
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10992569
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.18
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y4M17D
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
17073103
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
10614798
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
9.12
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y3M10D
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
16913005
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
7172134
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.68
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y
CY2019Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
13895017
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
6491196
CY2019Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58209745
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58209745
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50652238
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50652238
CY2019Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2716000
CY2018Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
7549000
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
9975000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 6pt; margin-left: 0in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates </div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 6pt; text-indent: 0.79in; margin-left: 0in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 18pt; margin-left: 0in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Concentration of Credit Risk </div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 6pt; text-indent: 0.79in; margin-left: 0in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company invests in a variety of financial instruments and, by its policy, limits the amount of credit exposure with any one issuer, industry or geographic area. </div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 12pt; text-indent: 0.79in; margin-left: 0in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable are typically unsecured and are concentrated in the pharmaceutical industry and government sector. Accordingly, the Company may be exposed to credit risk generally associated with pharmaceutical companies and government funded entities. The Company has not historically experienced any significant losses due to concentration of credit risk. </div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 12pt; text-indent: 0.79in; margin-left: 0in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable consists of the following (in thousands): </div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 12pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 12pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 76%;;margin : 0px auto;;text-align:left;;margin-left :auto;margin-right :auto;"><tr style="font-size: 8pt;"><td style="border-bottom: none; border-top: none; padding: 0px; vertical-align: bottom; font-size: 8pt;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 8pt; background: none; text-align: center; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 8pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="border-top: none; padding: 0in; vertical-align: bottom; font-size: 8pt;;width:;"><div style="font-size: 8pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 8pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;times new roman&quot;, times, serif; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td colspan="2" style="border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; white-space: nowrap; font-size: 8pt;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 8pt; text-align: center; white-space: nowrap; line-height: normal;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;">June 30,</div></div></div></div></td><td style="border-top: none; padding: 0in; vertical-align: bottom; white-space: nowrap; font-size: 8pt;"><div style="font-size: 8pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 8pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;times new roman&quot;, times, serif; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="border-top: none; padding: 0in; vertical-align: bottom; white-space: nowrap; font-size: 8pt;;width:;"><div style="font-size: 8pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 8pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;times new roman&quot;, times, serif; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td colspan="2" style="border-bottom: none; border-top: none; padding: 0in; vertical-align: bottom; white-space: nowrap; font-size: 8pt;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 8pt; text-align: center; white-space: nowrap; line-height: normal;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;">December 31,</div></div></div></div></td><td style="border-top: none; padding: 0in; vertical-align: bottom; white-space: nowrap; font-size: 8pt;"><div style="font-size: 8pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 8pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;times new roman&quot;, times, serif; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td></tr><tr style="font-size: 8pt;"><td style="border-bottom: none; border-top: none; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 8pt;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 8pt; background: none; text-align: center; line-height: normal; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 8pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="padding: 0in 0in 1pt; vertical-align: bottom; font-size: 8pt;;width:;"><div style="font-size: 8pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 8pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;times new roman&quot;, times, serif; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; white-space: nowrap; font-size: 8pt;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 8pt; text-align: center; white-space: nowrap; line-height: normal;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;">2019</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom; white-space: nowrap; font-size: 8pt;"><div style="font-size: 8pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 8pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;times new roman&quot;, times, serif; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td style="padding: 0in 0in 1pt; vertical-align: bottom; white-space: nowrap; font-size: 8pt;;width:;"><div style="font-size: 8pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 8pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;times new roman&quot;, times, serif; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-top: none; padding: 0in; vertical-align: bottom; white-space: nowrap; font-size: 8pt;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 8pt; text-align: center; white-space: nowrap; line-height: normal;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;">2018</div></div></div></div></td><td style="padding: 0in 0in 0.5pt; vertical-align: bottom; white-space: nowrap; font-size: 8pt;"><div style="font-size: 8pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-size: 8pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;times new roman&quot;, times, serif; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: none; padding: 0px; vertical-align: bottom; width: 84%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 0.17in; margin-top: 0px; text-indent: -0.17in; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Vifor (International) Ltd., and/or its affiliates, or collectively, Vifor</div></div></td><td style="background: rgb(204, 238, 255); border-top: none; padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; border-bottom: none; border-top: 0px none; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: left; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"><div style="white-space: nowrap; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: right; line-height: normal; white-space: nowrap; margin-right: 0in;"><div style="white-space: nowrap; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; white-space: nowrap; width: 4%; text-align: left;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(204, 238, 255); width: 4%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; white-space: nowrap; width: 1%; text-align: left;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: left; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; border-top: 0px none; padding: 0in; vertical-align: bottom; white-space: nowrap; width: 3.5%; text-align: right;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: right; line-height: normal; white-space: nowrap; margin-right: 0in;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">2,058</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; white-space: nowrap; width: 0.5%; text-align: left;"><div style="font-size: 10pt; font-family: &quot;times new roman&quot;, times, serif; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
ccxi Available For Sale Securities Debt Maximum Maturities Period
AvailableForSaleSecuritiesDebtMaximumMaturitiesPeriod
less than two years
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2019Q2 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
0
us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
CY2019Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2016Q2 ccxi Upfront Payment Received
UpfrontPaymentReceived
78000000
CY2019Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58250202
CY2016Q2 ccxi Non Refundable Up Front Payment Received
NonRefundableUpFrontPaymentReceived
85000000
dei Trading Symbol
TradingSymbol
CCXI
dei Entity Address State Or Province
EntityAddressStateOrProvince
DE
CY2016Q2 ccxi Non Refundable Upfront Payments Allocated For Issuance Of Common Stock
NonRefundableUpfrontPaymentsAllocatedForIssuanceOfCommonStock
7000000
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2016Q2 ccxi Non Refundable Upfront Payment Received In Equity Investment Shares
NonRefundableUpfrontPaymentReceivedInEquityInvestmentShares
3333333
CY2016Q2 ccxi Non Refundable Upfront Payments Allocated For Issuance Of Common Stock Per Share Value
NonRefundableUpfrontPaymentsAllocatedForIssuanceOfCommonStockPerShareValue
2.10
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
579000
us-gaap Operating Lease Payments
OperatingLeasePayments
565000
us-gaap Description Of Lessee Leasing Arrangements Operating Leases
DescriptionOfLesseeLeasingArrangementsOperatingLeases
The Company received a discounted lease rate during the first year of the agreement.
us-gaap Line Of Credit Facility Interest Rate Description
LineOfCreditFacilityInterestRateDescription
Advances under the Credit Facility bear an interest rate equal to the greater of either (i) 8.05% plus the prime rate as reported from time to time in The Wall Street Journal minus 4.75%, and (ii) 8.05%. At&#160;June&#160;30, 2019, the interest rate on the outstanding borrowings under the Credit Facility was&#160;8.80%. For advances made under the first and second tranches, the Company will make interest-only payments through July&#160;1, 2021, and will then repay the principal balance and interest on the advances in equal monthly installments after the interest-only period and continuing through December&#160;1, 2022.
CY2017Q4 us-gaap Debt Instrument Basis Spread On Variable Rate1
DebtInstrumentBasisSpreadOnVariableRate1
0.0805
ccxi Share Based Compensation Arrangement By Share Based Payment Award Options Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized
0
CY2019Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
220038000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
174926000
dei Document Type
DocumentType
10-Q
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2019-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Registrant Name
EntityRegistrantName
ChemoCentryx, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001340652
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Shell Company
EntityShellCompany
false
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Security12b Title
Security12bTitle
Common Stock
us-gaap Nature Of Operations
NatureOfOperations
<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;;width:4%;"><div style="font-weight:bold;display:inline;">1.</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description of Business </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">ChemoCentryx, Inc. (the Company) commenced operations in 1997. The Company is a clinical-stage biopharmaceutical company focused on developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. The Company&#8217;s principal operations are in the United States and it operates in one segment. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unaudited Interim Financial Information </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The financial information filed is unaudited. The Condensed Consolidated Financial Statements included in this report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for the fair statement of the results of operations for the interim periods covered and of the financial condition of the Company at the date of the interim balance sheet. The December&#160;31, 2018 Condensed Consolidated Balance Sheet was derived from audited financial statements. The results for interim periods are not necessarily indicative of the results for the entire year or any other interim period. The Condensed Consolidated Financial Statements should be read in conjunction with the Company&#8217;s financial statements and the notes thereto included in the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the year ended December&#160;31, 2018 filed with the Securities and Exchange Commission on March&#160;11, 2019.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1301000

Files In Submission

Name View Source Status
0001193125-19-212993-index-headers.html Edgar Link pending
0001193125-19-212993-index.html Edgar Link pending
0001193125-19-212993.txt Edgar Link pending
0001193125-19-212993-xbrl.zip Edgar Link pending
ccxi-20190630.xml Edgar Link completed
ccxi-20190630.xsd Edgar Link pending
ccxi-20190630_cal.xml Edgar Link unprocessable
ccxi-20190630_def.xml Edgar Link unprocessable
ccxi-20190630_lab.xml Edgar Link unprocessable
ccxi-20190630_pre.xml Edgar Link unprocessable
d710696d10q.htm Edgar Link pending
d710696dex101.htm Edgar Link pending
d710696dex311.htm Edgar Link pending
d710696dex312.htm Edgar Link pending
d710696dex321.htm Edgar Link pending
d710696dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g710696g38x60.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending